Editor's note

This ExpertREACT article was originally published on 20 June 2010 following the UK Health Protection Agency GBS symposium. Scientific data and pipeline positions described reflect the state of knowledge at that date.

A pathogen not fully addressed by antibiotics

Group B Streptococcus (GBS, Streptococcus agalactiae) was first reported as a human pathogen in 1938, becoming the leading cause of neonatal septicaemia and meningitis throughout the 1970s with incidences ranging from 1 to 3 per 1,000 live births - equating to 8-10,000 cases per year in the US at that time. GBS is vertically transmitted during childbirth from approximately 10-30% of colonised pregnant women; approximately 50% of neonates become colonised, of whom around 2% develop early-onset (EOD, days 0-6) or late-onset (LOD, days 7-89) disease. Around 25-50% of survivors of GBS meningitis have permanent neurological sequelae. Successive US CDC/ACOG/AAP screening and intrapartum antibiotic prophylaxis (IAP) guidelines in 1996 and 2002 substantially reduced EOD, but LOD incidence remained unchanged.

The UK Health Protection Agency (HPA) Centre of Infections symposium on neonatal GBS brought together experts from public health, neonatology, midwifery, paediatrics and vaccinology. Attendees acknowledged that despite IAP, the pathogen remained a significant cause of morbidity and mortality. A major theme was that IAP was not a solution to LOD and did not address adult-onset GBS disease - where incidence in the 15-64 age group had increased 48% between 1999 and 2005 according to Active Bacterial Core surveillance data.

Neurological sequelae in GBS meningitis survivors
25-50%
Of neonatal GBS meningitis survivors have permanent neurological sequelae, highlighting the severity of this pathogen for affected families

Novartis Vaccines' glycoconjugate approach

Novartis Vaccines was identified as the company most actively pursuing a GBS vaccine - developing a trivalent glycoconjugate composed of serotypes Ia, Ib and III. These three serotypes together accounted for approximately 65-86% of EOD across US, South African and Malawian populations. The symposium confirmed that a preventative GBS vaccine targeting pregnant women was scientifically feasible and represented the most promising long-term intervention. A Phase III efficacy trial in pregnant women of greater than 50,000 participants was projected as the eventual key study, with ongoing work to build the epidemiological data infrastructure in planned trial sites internationally.